PICC导管穿刺点大量渗血?这样处理快速止血!

2021-12-20 护士网 护士网

PICC,又称“经外周静脉穿刺中心静脉置管”,是利用导管从外周静脉进行穿刺,导管直达靠近心脏的大静脉,由于大静脉的血流速度很快,可以迅速冲稀化疗药物,防止药物对血管的刺激。

患者,男64岁,肝硬化,食管静脉曲张,消化道出血。血小板低,血色素低,静脉血管条件差,给予留置PICC导管。

 

11月2日颈部留置pIcc导管,11月4日2:00护士小张发现pIcc导管穿刺点开始大量渗血,小张护士给予换药,并用纱布按压。

 

8:00渗血,如下图所示

 

图片

 

8:30 运用明胶海绵加无菌纱布开始换药,加压止血

 

图片

 

第一步:用75%酒精和2%葡萄糖氯已定乙醇溶液消毒皮肤导管,用无菌棉签按住穿刺点。

 

图片

 

第二步:将明胶海绵对折放在穿刺点,继续用无菌棉签按压。

 

图片

 

第三步:贴上大透明膜,继续用无菌棉签按压。

 

图片

 

第四步:用无菌纱布在透明膜上按压穿刺点,一个小时。

 

图片

 

第五步:按压1个小时后,用两张IV3000的大透明膜贴紧穿刺点上方的无菌纱布。

 

每班观察患者穿刺点的渗血情况,如一张图那样及时更换,入渗血量不大,可以酌情一至两天换药。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2005327, encodeId=a578200532e18, content=<a href='/topic/show?id=2fbee5433cb' target=_blank style='color:#2F92EE;'>#穿刺点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75433, encryptionId=2fbee5433cb, topicName=穿刺点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Apr 22 15:37:24 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182415, encodeId=02b41182415ba, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29255410682, createdName=ms2000000747612687, createdTime=Sun Jan 09 07:15:02 CST 2022, time=2022-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263105, encodeId=2237126310571, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311971, encodeId=2d4c13119e1b9, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414572, encodeId=34e414145e289, content=<a href='/topic/show?id=7c2b142565d' target=_blank style='color:#2F92EE;'>#PICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14256, encryptionId=7c2b142565d, topicName=PICC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c6b3060279, createdName=tomyang87, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462091, encodeId=ac5f1462091cc, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36506466438, createdName=zhs3884, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2005327, encodeId=a578200532e18, content=<a href='/topic/show?id=2fbee5433cb' target=_blank style='color:#2F92EE;'>#穿刺点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75433, encryptionId=2fbee5433cb, topicName=穿刺点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Apr 22 15:37:24 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182415, encodeId=02b41182415ba, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29255410682, createdName=ms2000000747612687, createdTime=Sun Jan 09 07:15:02 CST 2022, time=2022-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263105, encodeId=2237126310571, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311971, encodeId=2d4c13119e1b9, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414572, encodeId=34e414145e289, content=<a href='/topic/show?id=7c2b142565d' target=_blank style='color:#2F92EE;'>#PICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14256, encryptionId=7c2b142565d, topicName=PICC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c6b3060279, createdName=tomyang87, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462091, encodeId=ac5f1462091cc, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36506466438, createdName=zhs3884, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
    2022-01-09 ms2000000747612687

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2005327, encodeId=a578200532e18, content=<a href='/topic/show?id=2fbee5433cb' target=_blank style='color:#2F92EE;'>#穿刺点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75433, encryptionId=2fbee5433cb, topicName=穿刺点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Apr 22 15:37:24 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182415, encodeId=02b41182415ba, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29255410682, createdName=ms2000000747612687, createdTime=Sun Jan 09 07:15:02 CST 2022, time=2022-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263105, encodeId=2237126310571, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311971, encodeId=2d4c13119e1b9, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414572, encodeId=34e414145e289, content=<a href='/topic/show?id=7c2b142565d' target=_blank style='color:#2F92EE;'>#PICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14256, encryptionId=7c2b142565d, topicName=PICC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c6b3060279, createdName=tomyang87, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462091, encodeId=ac5f1462091cc, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36506466438, createdName=zhs3884, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
    2021-12-22 jeanqiuqiu
  4. [GetPortalCommentsPageByObjectIdResponse(id=2005327, encodeId=a578200532e18, content=<a href='/topic/show?id=2fbee5433cb' target=_blank style='color:#2F92EE;'>#穿刺点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75433, encryptionId=2fbee5433cb, topicName=穿刺点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Apr 22 15:37:24 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182415, encodeId=02b41182415ba, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29255410682, createdName=ms2000000747612687, createdTime=Sun Jan 09 07:15:02 CST 2022, time=2022-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263105, encodeId=2237126310571, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311971, encodeId=2d4c13119e1b9, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414572, encodeId=34e414145e289, content=<a href='/topic/show?id=7c2b142565d' target=_blank style='color:#2F92EE;'>#PICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14256, encryptionId=7c2b142565d, topicName=PICC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c6b3060279, createdName=tomyang87, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462091, encodeId=ac5f1462091cc, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36506466438, createdName=zhs3884, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
    2021-12-22 rgjl
  5. [GetPortalCommentsPageByObjectIdResponse(id=2005327, encodeId=a578200532e18, content=<a href='/topic/show?id=2fbee5433cb' target=_blank style='color:#2F92EE;'>#穿刺点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75433, encryptionId=2fbee5433cb, topicName=穿刺点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Apr 22 15:37:24 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182415, encodeId=02b41182415ba, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29255410682, createdName=ms2000000747612687, createdTime=Sun Jan 09 07:15:02 CST 2022, time=2022-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263105, encodeId=2237126310571, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311971, encodeId=2d4c13119e1b9, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414572, encodeId=34e414145e289, content=<a href='/topic/show?id=7c2b142565d' target=_blank style='color:#2F92EE;'>#PICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14256, encryptionId=7c2b142565d, topicName=PICC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c6b3060279, createdName=tomyang87, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462091, encodeId=ac5f1462091cc, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36506466438, createdName=zhs3884, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
    2021-12-22 tomyang87
  6. [GetPortalCommentsPageByObjectIdResponse(id=2005327, encodeId=a578200532e18, content=<a href='/topic/show?id=2fbee5433cb' target=_blank style='color:#2F92EE;'>#穿刺点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75433, encryptionId=2fbee5433cb, topicName=穿刺点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Fri Apr 22 15:37:24 CST 2022, time=2022-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182415, encodeId=02b41182415ba, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29255410682, createdName=ms2000000747612687, createdTime=Sun Jan 09 07:15:02 CST 2022, time=2022-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263105, encodeId=2237126310571, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311971, encodeId=2d4c13119e1b9, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414572, encodeId=34e414145e289, content=<a href='/topic/show?id=7c2b142565d' target=_blank style='color:#2F92EE;'>#PICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14256, encryptionId=7c2b142565d, topicName=PICC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c6b3060279, createdName=tomyang87, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462091, encodeId=ac5f1462091cc, content=<a href='/topic/show?id=32fd933505' target=_blank style='color:#2F92EE;'>#ICC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9335, encryptionId=32fd933505, topicName=ICC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36506466438, createdName=zhs3884, createdTime=Wed Dec 22 05:37:24 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
    2021-12-22 zhs3884

相关资讯

J Thromb Haemost:噬血细胞性淋巴组织细胞增生症成人出血和血栓栓塞发生率及其对总生存率的影响

在噬血细胞性淋巴组织细胞增生症的成人中,VTE似乎比之前描述的更常见,并且是患者死亡的预测因子,尽管这可能是由于未经调整的混杂因素所致。由于出血率高,VTE的预防和治疗具有挑战性。

BMJ:丹麦和挪威的牛津-阿斯利康ChAdOx1-S疫苗接种后的动脉事件、静脉血栓栓塞、血小板减少和出血

ChAdOx1-S疫苗接种后栓塞(包括脑静脉血栓形成)的发生率高于正常水平。这些事件的绝对风险很小。对于其余的安全结果,结果令人放心,血小板减少/凝血障碍和出血的发生率略高,这可能受到加强监测的影响。

J Gastrointest Surg:内窥镜粘膜下层剥离术后禁食期间静脉注射质子泵抑制剂对预防出血的影响

对于接受内窥镜粘膜下剥离术(ESD)的患者的最佳围手术期策略,目前尚未达成共识。近日,一项单一中心进行的前瞻性、随机、双盲、安慰剂对照试验调查了在ESD后禁食期间静脉注射质子泵抑制剂(PPI)对ESD

Eur Heart J:经皮冠状动脉介入治疗的癌症患者90天内因急性心肌梗塞和出血再入院分析

PCI后,癌症患者因AMI或出血再入院的风险增加,其风险大小取决于癌症类型和有无转移。

J Am Coll Cardiol:大多ACS住院患者存在无明显出血的血红蛋白降低,且与一年死亡率相关

当代对出血终点的定义主要局限于临床显性事件。血红蛋白是否降低、是否伴有显性出血、是否会对急性冠脉综合征(ACS)患者的预后产生不利影响均尚不清楚。

孩子胳膊出现密集出血点,检验科采血给孩子扎坏了?

一天下午一位年轻妈妈抱着孩子来到检验科标本签收窗口,从面部表情可以看出她非常的气愤也非常的着急,他对我说“你们科采血人员采血时扎坏我家孩子毛细血管了,你看看这个胳膊都成什么样了,这还是好点以后的,刚开